TrialThe New England journal of medicine2018
Trial of Solanezumab for Mild Dementia Due to Alzheimer's Disease.
Lawrence S Honig et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
536 papers cite itlatest 60 shown
this paperpooled ittrialcites it